comparemela.com

Latest Breaking News On - Norcliffe capital limited - Page 1 : comparemela.com

Follow the Money: Single-Cell Multiomics, Data Networks, Security

April 1, 2021 By Bio-IT World Staff April 1, 2021 | New investment funds for late-stage companies and public health. Next-gen genomic medicines and single-cell multiomics get cash, and PatientsLikeMe raises a new round of funding to expand.   $969M Investment Fund for Early to Late-Stage Companies Foresite Capital, a multi-stage healthcare and life sciences investment firm, has announced its fifth and largest fundraise with $969 million in capital commitments, significantly oversubscribed above its original target. The offering comprises Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages that are solving some of the biggest inefficiencies and pain points of the $10 trillion global healthcare market. Foresite Capital now has ~$4 billion in assets under management. Press release.

ClinSpec Diagnostics reaches funding target of £3 5m

ClinSpec Diagnostics reaches funding target of £3.5m 5th March 2021 Glasgow-based ClinSpec Diagnostics has secured an additional £1.1m investment, reaching its round two funding target of £3.5m. ClinSpec, a spin-out company from the University of Strathclyde’s Department of Pure and Applied Chemistry, is aiming to develop liquid biopsies for the early detection of cancer. The new £1.1m investment from the latest funding round comes from a range of investors, including Norcliffe Capital Limited, the University of Strathclyde, Eos Advisory and the founders. The first £2.4m was secured in 2020, with that funding round led by Mercia’s EIS Funds with Scottish Enterprise, SIS Ventures, Eos Advisory and the University of Strathclyde.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.